Aspirin can stimulate luminol-enhanced chemiluminescence of activated platelets

Platelets

Volumn 21, Issue 6, 2010, Pages 486-489

  Gabbasov, Zufar ^a   Ivanova, Oksana ^b   Kogan Yasny, Victor ^c   Vasilieva, Elena ^b  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^c NONE   (Russian Federation)

Author keywords

Aspirin; Chemiluminescence; Luminol; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; LUMINOL; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

AGED; ASPIRIN; BLOOD PLATELETS; CHEMILUMINESCENT MEASUREMENTS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LUMINOL; MALE; MIDDLE AGED; PLATELET ACTIVATION; REACTIVE OXYGEN SPECIES;

EID: 77955911161     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537101003777947     Document Type: Article

References (15)

1. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004;4:181-189.
2. Edderkaoui M, Hong P, Vaquero EC, Lee JK, Fischer L, Friess H, Buchler MW, Lerch MM, Pandol SJ, Gukovskaya AS. Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. Am J Physiol Gastrointest Liver Physiol 2005;289:G1137-1147.
3. Wachowicz B, Olas B, ZbikowskaHM,Buczyń ski A. Generation of reactive oxygen species in blood platelets. Platelets 2002;13:175-182.
4. Wörner P. Arachidonic acid-induced chemiluminescence of human platelets: Contribution of the prostaglandin and lipoxygenase pathways. Thromb Haemost 1981;46:584-589.
5. Herbertsson H, Bengtsson T. Role of platelets and the arachidonic acid pathway in the regulation of neutrophil oxidase activity. Scand J Clin Lab Invest 2001;61:641-649.
6. Vilim V, Wilhelm J. What do we measure by a luminoldependent chemiluminescence of phagocytes? Free Radic Biol Med 1989;6:623-629.
7. Drábiková K, Jancinová V, Nosál R, Danihelová E. Human blood platelets, PMN leukocytes and their interactions in vitro. Responses to selective and non-selective stimuli. Gen Physiol Biophys 2000;19:393-404.
8. Montrucchio G, Alloatti G, Camussi G. Role of plateletactivating factor in cardiovascular pathophysiology. Physiol Rev 2000;80:1669-1699.
9. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002;30(5 Suppl):S294-S301.
10. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
11. Frelinger 3rd AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate- dependent but cyclooxygenase-1- and cyclooxygenase- 2-independent pathway: A 700-patient study of aspirin resistance. Circulation 2006;113:2888-2896.
12. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, Vered Z, Krakover R, Kaluski E, Kornberg A. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147:293-300.
13. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: nvolvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006;4(6):1271-1278.
14. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5(Suppl 1):230-237.
15. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, Faille D, Morange PE, Alessi MC, Bonnet JL. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 2009;157:889-893.